A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ling, Xiang ^a   Cao, Shousong ^a   Cheng, Qiuying ^a   Keefe, James T ^a   Rustum, Youcef M ^a   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; FIRTECAN; FL 118; FLUOROURACIL; GEMCITABINE; INHIBITOR OF APOPTOSIS PROTEIN 2; IRINOTECAN; OXALIPLATIN; PROTEIN MCL 1; PROTEIN P53; SURVIVIN; TOPOTECAN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION (PARAMETERS); DRUG DOSE ESCALATION; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; REPORTER GENE; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIOXOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLIZINES; INHIBITOR OF APOPTOSIS PROTEINS; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84866534987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045571     Document Type: Article

References (82)

1. Altieri DC, (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
2. Altieri DC, (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem J 430: 199-205.
3. Altieri DC, (2008) New wirings in the survivin networks. Oncogene 27: 6276-6284.
4. Li F, Ling X, (2006) Survivin Study: An update of "What is the next wave?". J Cell Physiol 208: 476-486.
5. Wu J, Apontes P, Song L, Liang P, Yang L, et al. (2007) Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res 35: 2390-2402.
6. Wu J, Ling X, Pan D, Apontes P, Song L, et al. (2005) Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence selective DNA-binding antitumor agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity. J Biol Chem 280: 9745-9751.
7. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, et al. (2009) 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 69: 4468-4475.
8. Wang S, Huang X, Lee CK, Liu B, (2010) Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29: 4225-4236.
9. Trabulo S, Cardoso AM, Santos-Ferreira T, Cardoso AL, Simoes S, et al. (2011) Survivin Silencing as a Promising Strategy To Enhance the Sensitivity of Cancer Cells to Chemotherapeutic Agents. Mol Pharm 8: 1120-1131.
10. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, et al. (2011) Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 118: 2191-2199.
11. Peng X, Karna P, Cao Z, Jiang B, Zhou M, et al. (2006) Cross-talk between epidermal growth factor receptor and HIF-1 signal pathways increases resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 281: 25903-25914.
12. Ling X, He X, Apontes P, Cao F, Azrak RG, et al. (2009) Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res 1: 393-405.
13. Guo Y, Mantel C, Hromas RA, Broxmeyer HE, (2008) Oct 4 is Critical for Survival/Antiapoptosis of Murine Embryonic Stem Cells Subjected to Stress. Effects Associated with STAT3/Survivin. Stem Cells 26: 30-34.
14. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, et al. (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667.
15. Li F, Cheng Q, Ling X, Stablewski A, Tang L, et al. (2010) Generation of a Novel Transgenic Mouse Model for Bioluminescent Monitoring of Survivin Gene Activity in Vivo at Various Pathophysiological Processes. Survivin Expression Overlaps with Stem Cell Markers. Am J Pathol 176: 1629-1638.
16. Fukuda S, Abe M, Onishi C, Taketani T, Purevsuren J, et al. (2011) Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol 2011: 946936.
17. Singh A, Settleman J, (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
18. Glinsky GV, (2006) Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 5: 1208-1216.
19. Altieri DC, (2003) Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5: 447-452.
20. Wheatley SP, McNeish IA, (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247: 35-88.
21. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021.
22. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, et al. (2010) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102: 614-621.
23. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, et al. (2012) Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3: 179-197.
24. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, et al. (2008) Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. J Clin Oncol 26: 5198-5203.
25. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, et al. (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27: 4481-4486.
26. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, et al. (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7: 457-468.
27. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, et al. (2006) Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98: 1068-1077.
28. Meli M, Pennati M, Curto M, Daidone MG, Plescia J, et al. (2006) Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem 49: 7721-7730.
29. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1: 461-466.
30. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, et al. (2008) SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 7: 2736-2745.
31. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584.
32. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL, (2000) Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151: 1575-1582.
33. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, et al. (2000) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10: 1319-1328.
34. Li F, (2003) Survivin Study: What is the next wave? J Cell Physiol 197: 8-29.
35. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC, (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127.
36. Reed JC, Reed SI, (1999) Survivin' cell-separation anxiety. Nat Cell Biol 1: E199-200.
37. Li F, Brattain MG, (2006) Role of the Survivin Gene in Pathophysiology. Am J Pathol 169: 1-11.
38. Li F, Ling X, Huang H, Brattain L, Apontes P, et al. (2005) Differential regulation of survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24: 1385-1395.
39. Tang L, Ling X, Liu W, Das GM, Li F, (2012) Transcriptional inhibition of p21(WAF1/CIP1) gene (CDKN1) expression by survivin is at least partially p53-dependent: Evidence for survivin acting as a transcription factor or co-factor. Biochemical and Biophysical Research Communications 421: 249-254.
40. Zhang M, Yang J, Li F, (2006) Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res 25: 391-402.
41. Li F (2009) Compositions and methods for identifying agents that alter expression of survivin. In: USPTO, editor. USPTO (US 7,569,221 B2). US 7,569,221 B2 ed. USA: Health Research Inc., Roswell Park Cancer Institute. 1-22.
42. DiSaia PJ, Sinkovics JG, Rutledge FN, Smith JP, (1972) Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. American journal of obstetrics and gynecology 114: 979-989.
43. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F, (2010) Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res 29: 8.
44. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. (2007) Mesothelin expression in human lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 1571-1575.
45. Ling X, Yang J, Tan D, Ramnath N, Younis T, et al. (2005) Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49: 353-361.
46. Li X, Yang Y, Ashwell JD, (2002) TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416: 345-347.
47. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, et al. (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80.
48. Ling X, Bernacki RJ, Brattain MG, Li F, (2004) Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. J Biol Chem 279: 15196-15203.
49. Gerber HP, Dixit V, Ferrara N, (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. The Journal of biological chemistry 273: 13313-13316.
50. Marani M, Hancock D, Lopes R, Tenev T, Downward J, et al. (2004) Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23: 2431-2441.
51. Roca H, Varsos Z, Pienta KJ, (2008) CCL2 protects prostate cancer PC3 cells from autophagic death via PI3K/AKT-dependent survivin up-regulation. J Biol Chem 283: 25057-25073.
52. Rustum YM, Toth K, Seshadri M, Sen A, Durrani FA, et al. (2010) Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. J Oncol 2010: 396286.
53. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A, (2002) Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Current cancer drug targets 2: 103-123.
54. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, et al. (2009) Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anti-cancer drugs 20: 519-524.
55. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, et al. (2009) Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC cancer 9: 339.
56. Richter SN, Nadai M, Palumbo M, Palu G, (2009) Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer. Cancer chemotherapy and pharmacology 64: 199-200.
57. Barth SW, Briviba K, Watzl B, Jager N, Marko D, et al. (2010) In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats. Biotechnology journal 5: 321-327.
58. Cao S, Durrani FA, Rustum YM, (2004) Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10: 2561-2569.
59. Ruckert F, Samm N, Lehner AK, Saeger HD, Grutzmann R, et al. (2010) Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer 10: 379.
60. Montazeri Aliabadi H, Landry B, Mahdipoor P, Uludag H, (2011) Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. Mol Pharm 8: 1821-1830.
61. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, et al. (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proceedings of the National Academy of Sciences of the United States of America 94: 10057-10062.
62. Bhattacharya S, Ray RM, Johnson LR, (2005) STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 392: 335-344.
63. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, et al. (2008) Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 10: 1183-1194.
64. Jang BC, Paik JH, Jeong HY, Oh HJ, Park JW, et al. (2004) Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochemical pharmacology 68: 263-274.
65. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, et al. (2006) Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 5: 2737-2746.
66. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, et al. (2007) Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 2144-2150.
67. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, et al. (2008) Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Molecular cancer research: MCR 6: 42-52.
68. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, et al. (2004) An IAP-IAP Complex Inhibits Apoptosis. J Biol Chem 279: 34087-34090.
69. Markowitz SD, Bertagnolli MM, (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. The New England journal of medicine 361: 2449-2460.
70. Rodel F, Frey B, Leitmann W, Capalbo G, Weiss C, et al. (2008) Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71: 247-255.
71. Raviv Z, Zilberberg A, Cohen S, Reischer-Pelech D, Horrix C, et al. (2011) Methyl jasmonate downregulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. Br J Pharmacol 164: 1433-1444.
72. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, et al. (2011) Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 10: 188-193.
73. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, et al. (2012) Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 105: 520-528.
74. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC, (2003) Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209.
75. Connolly K, Mitter R, Muir M, Jodrell D, Guichard S, (2009) Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer chemotherapy and pharmacology 64: 307-316.
76. Dai Y, Qiao L, Chan KW, Zou B, Ma J, et al. (2008) Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. International journal of cancer Journal international du cancer 122: 2858-2863.
77. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, et al. (2008) A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27: 6012-6022.
78. Qiao L, Li GH, Dai Y, Wang J, Li Z, et al. (2009) Gene expression profile in colon cancer cells with respect to XIAP expression status. International journal of colorectal disease 24: 245-260.
79. Tu SP, Sun YW, Cui JT, Zou B, Lin MC, et al. (2010) Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression. Cancer 116: 1252-1263.
80. Lee M, Lapham A, Brimmell M, Wilkinson H, Packham G, (2008) Inhibition of proteasomal degradation of Mcl-1 by cobalt chloride suppresses cobalt chloride-induced apoptosis in HCT116 colorectal cancer cells. Apoptosis 13: 972-982.
81. Miura K, Karasawa H, Sasaki I, (2009) cIAP2 as a therapeutic target in colorectal cancer and other malignancies. Expert opinion on therapeutic targets 13: 1333-1345.
82. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, et al. (2012) A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 23: 968-973.